drug · small molecule

LYBALVI

updated 2mo ago

by $ALKS Alkermes plc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 27 investigational indications.

targets

D2-like dopamine receptor5-hydroxytryptamine receptor 2C5-hydroxytryptamine receptor 2A

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

LYBALVI

trade names

Arkolamyl, Olansek, Olanzapine, Olanzapine apotex, Olanzapine cipla (previously olanzapine neopharma), Olanzapine component of lybalvi

generic

OLANZAPINE

MOA

12.1 Mechanism of Action The mechanism of action of olanzapine is unclear; however, its efficacy in the treatment of schizophrenia or bipolar I disorder could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism. The mechanism of action of samidorphan could be mediated through opioid receptor antagonism.

indication

1 INDICATIONS AND USAGE LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of: Schizophrenia in adults ( 1 ) Bipolar I disorder in adults ( 1 ) Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment

LYBALVI

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying LYBALVI